Identification of biomarkers to drive treatment using cell-free DNA allows dynamic and safe assessment of tumor biology representing an important advance adding to tissue-based genotyping. Caution must be exercised interpreting commercial matching information as validation is often lacking, and true matching is feasible in a minority of patients. See related article by Vidula et al., p. 3404
No takes yet. Share an insight, caveat, or question.
Rugo et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: